Published in J Am Coll Cardiol on March 17, 2004
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133) | NCT00338260
Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med (2007) 1.54
Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks Versus Whites. J Am Coll Cardiol (2015) 1.45
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation (2008) 1.44
Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol (2010) 1.43
Research Needs to Improve Hypertension Treatment and Control in African Americans. Hypertension (2016) 0.99
Left ventricular hypertrophy among black hypertensive patients: focusing on the efficacy of angiotensin converting enzyme inhibitors. BMC Res Notes (2014) 0.82
RAS blockade for every diabetic patient: pro and con. Diabetes Care (2011) 0.79
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. Vasc Health Risk Manag (2007) 0.77
Are racial differences in antihypertensive responsiveness reflected in usage after stroke? J Stroke Cerebrovasc Dis (2007) 0.75
Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism. Curr Hypertens Rep (2009) 0.75
Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity. Intern Emerg Med (2016) 0.75
Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. Patient Relat Outcome Meas (2011) 0.75
Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis. Biomed Pharmacother (2017) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Recommendations for chamber quantification. Eur J Echocardiogr (2006) 11.39
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 7.86
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
The revised Ghent nosology for the Marfan syndrome. J Med Genet (2010) 6.87
Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation (2004) 6.15
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension (2007) 5.61
Retracted Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet (2007) 5.17
APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens (2007) 4.59
Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol (2007) 4.49
Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension (2007) 4.20
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA (2004) 3.88
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA (2004) 3.68
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27
Sodium intake and mortality in the NHANES II follow-up study. Am J Med (2006) 3.24
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.10
[Prevention of myocardial infarction and stroke with statins]. Tidsskr Nor Laegeforen (2004) 2.96
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care (2006) 2.90
Retracted Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J (2009) 2.83
Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med (2014) 2.81
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med (2006) 2.81
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet (2004) 2.78
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol (2010) 2.77
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69
Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N Engl J Med (2005) 2.68
Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med (2006) 2.68
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J (2008) 2.65
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care (2005) 2.59
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation (2004) 2.56
Cadmium exposure and incident cardiovascular disease. Epidemiology (2013) 2.55
Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol (2008) 2.52
Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis (2012) 2.51
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension (2007) 2.44
Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol (2010) 2.43
Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol (2002) 2.41
Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis (2009) 2.39